Skip to search formSkip to main contentSkip to account menu

Adenosine-A2A Receptor Antagonist CPI-444

Known as: Adenosine-A2A Receptor-Targeting Agent CPI-444, CPI-444 
A small molecule immune checkpoint inhibitor of the adenosine A2A receptor (ADORA2A) with potential antineoplastic activity. Upon oral administration… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Adenosine checkpoint agent blazes a trail, joins immunotherapy roster
A two-and-a-half-year-old biotech with an adenosine-targeted checkpoint drug plans to move into pivotal trials in near record… 
2017
2017
Vertex CF data wow Wall Street
2017
2017
Go-ahead for first anti-IL-23 mAb to treat psoriasis
2017
2017
Abstract 5593: Inhibition of A2AR induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical and clinical studies
Adenosine signaling via A2A receptor (A2AR) on immune cells suppresses anti-tumor immunity and limits the efficacy of… 
2016
2016
Abstract 2337: The adenosine A2A receptor antagonist CPI-444 blocks adenosine-mediated T-cell suppression and exhibits antitumor activity alone and in combination with anti-PD-1 and anti-PD-L1
Elevated levels of extracellular adenosine within the tumor microenvironment create an immunosuppressive niche that promotes… 
2016
2016
Abstract PR04: CPI-444: A potent and selective inhibitor of A2AR induces antitumor responses alone and in combination with anti-PD-L1 in preclinical and clinical studies
Elevated extracellular adenosine in the tumor microenvironment generates an immunosuppressive niche that promotes tumor growth… 
2016
2016
Phase 1/1b multicenter trial of the adenosine A2a receptor antagonist (A2aR) CPI-444 as single agent and in combination with atezolizumab (ATZ) in patients(Pts) with advanced cancers
Background: Adenosine is an extracellular signaling molecule thatincreases in response to acute tissue injury/inflammation to… 
2016
2016
Abstract 4364: Adenosine A2a receptor blockade as a means of enhancing immune checkpoint inhibition and adoptive T-cell therapy
Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA Adenosine signaling through the A2a receptor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)